Alexa 488 labeled antibodies

Manufactured by Thermo Fisher Scientific

Sourced in United Kingdom, Germany

Alexa 488-labeled antibodies are fluorescently-conjugated antibodies that emit green fluorescence when excited with blue light. They can be used for a variety of applications in biological research, such as immunofluorescence microscopy and flow cytometry, to detect and visualize target proteins or cells.

Automatically generated - may contain errors

Lab products found in correlation

Mhc class 1, by BioLegend (1 mentions) Anti hsp70, by Abcam (1 mentions) Anti calreticulin, by Abcam (1 mentions) Pd l1, by Thermo Fisher Scientific (1 mentions) Mhcii, by BioLegend (1 mentions) Atp determination kit, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

Alexa 488-labeled goat anti-rabbit antibodies Alexa Fluor® 488- or 594-labeled secondary antibodies Alexa Fluor 488 labeled anti-rabbit or anti-mouse secondary antibodies Anti-rabbit Alexa 488-labeled secondary antibodies Alexa Fluor 488- and Alexa Fluor 549-labeled secondary antibodies Alexa 488 and 546 dye-labeled antibodies Alexa Fluor 488 (A488) or Cy3-labeled secondary antibodies Alexa Fluor 488-or Alexa Fluor 568-labeled goat anti-rabbit antibodies Mitochondria-GFP Alexa Fluor 488 or 546 labeled secondary antibodies [donkey anti-mouse IgG (H+L)] Alexa Fluor 488 Labeled Donkey anti-rat IgG Antibodies

2 protocols using alexa 488 labeled antibodies

Immunogenic Cell Death Markers in Reovirus-Treated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

FACS analysis was used to determine expression of ICD determinants on the surfaces of reovirus-treated cells. Cell lines untreated, treated with reovirus (MOIs at IC₅₀, 3 for PC3, 40 for DU145, and 0.06 for TRAMP-C2), or exposed to heat-inactivated reovirus for 24, 48, and 72 h were incubated with anti-HSP70 (clone: EPR16892), anti-calreticulin (rabbit polyclonal), and a rabbit isotype control (Abcam, UK). Additional stains included major histocompatibility complex (MHC) class I (clone: W6132; BioLegend, UK), CD80 (clone: 2D10; eBioscience, UK), FAS (rabbit polyclonal; Abcam, UK), and CD274 (PD-L1) (M1H2; BioLegend, UK). Relevant secondary Alexa 488-labeled antibodies were subsequently applied (Molecular Probes, UK). For the detection of murine markers on the TRAMP-C2 line, the additional following antibodies were used: anti-mouse H-2 (clone: M1/42; BioLegend, UK), anti-mouse CD80 (clone: 16-10A1; BioLegend, UK), and anti-mouse CD274 (PD-L1) (clone: M1H7; eBioscience, UK).
Released ATP and HMGB1 levels in cell supernatants of cell lines untreated, treated with reovirus, or exposed to heat-inactivated reovirus for 24, 48, and 72 h were detected using a standard ATP determination kit according to the manufacturer’s (Molecular Probes) instructions or measured by an HMGB1 ELISA (IBL International, Hamburg, Germany).

Annels N.E., Simpson G.R., Denyer M., Arif M., Coffey M., Melcher A., Harrington K., Vile R, & Pandha H. (2020). Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors. Molecular Therapy Oncolytics, 20, 434-446.

+ Open protocol

+ Expand

Immunogenic Profiling of Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

FACS analysis was used to determine expression of ICD determinants on the surfaces of treated cells. Cell lines untreated, treated with Mitomycin-C (0.5 μg/mL) for 1 hr, or exposed to CVA21 for 24–72 hr with or without prior Mitomycin-C treatment were harvested and incubated with anti-HSP70, anti-calreticulin, and an isotype control (Abcam). Additional stains included MHCII (BioLegend), CD80 (eBioscience), FAS (Abcam), and PD-L1 (eBioscience). Relevant secondary Alexa-488-labeled antibodies were subsequently applied (Molecular Probes).
Released HMGB1 was measured in the conditioned media of cell lines by ELISA (IBL International, Hamburg, Germany) and extracellular ATP by ATP determination kit (Molecular Probes).

Annels N.E., Arif M., Simpson G.R., Denyer M., Moller-Levet C., Mansfield D., Butler R., Shafren D., Au G., Knowles M., Harrington K., Vile R., Melcher A, & Pandha H. (2018). Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Molecular Therapy Oncolytics, 9, 1-12.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!